Bas van Loo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bas van Loo has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jeroen Leijten
Department of Bioengineering Technologies, Faculty of Science and Technology, TechMedCentre, University of Twente, 7522 NB, Enschede, the Netherlands
6 shared publications Maik Schot
Department of Developmental BioEngineering Faculty of Science and Technology Technical Medical Centre University of Twente Drienerlolaan 5 Enschede 7522 NB The Netherlands
2 shared publications- Marcel Karperien
Department of Developmental BioEngineering, Faculty of Science and Technology and TechMed Centre, University of Twente, Drienerlolaan 5, 7522 NB Enschede, The Netherlands
2 shared publications - Nuno Araújo-Gomes
Department of Bioengineering Technologies, Faculty of Science and Technology, TechMedCentre, University of Twente, 7522 NB, Enschede, the Netherlands
2 shared publications Tom Kamperman
Department of Developmental BioEngineering Faculty of Science and Technology Technical Medical Centre University of Twente Drienerlolaan 5 Enschede 7522 NB The Netherlands
2 shared publications- Tom Kamperman
Department of Developmental BioEngineering Faculty of Science and Technology Technical Medical Centre University of Twente Drienerlolaan 5 Enschede 7522NB The Netherlands
2 shared publications
Latest Publications
- Open Access
Intracellular crowding links dimensionality to cell fate through a mechano-metabolic signalling axis
Three-dimensional (3D) cell culture systems exhibit more native-like cell behaviour compared to conventional two-dimensional (2D) cell culture systems. However, it remains largely unknown how dimensionality alters cell behaviour. Here, we identify intracellular crowding as a key biophysical parameter altered by cell culture dimensionality, which directs cell fate over a mechano-metabolic axis. Specifically, culture dimensionality controlled intracellular crowding by altering cell volume, which was confirmed across multiple cell types and cell culture platforms. Using chondrogenesis as a model system, we demonstrated that dimensionality-induced intracellular changes lead to improved chondrogenic stem cell differentiation in microtissue culture via a FOXO1 signalling axis. Our findings highlight intracellular crowding as an important parameter of cell culture systems, and present a novel strategy for engineering biomimetic cell culture systems, which has implications for a multitude of applications including disease modelling, in vitro drug screening models, developmental biology, and cell-based therapies.
Open AccessIntracellular crowding links dimensionality to cell fate through a mechano-metabolic signalling axis
Three-dimensional (3D) cell culture systems exhibit more native-like cell behaviour compared to conventional two-dimensional (2D) cell culture systems. However, it remains largely unknown how dimensionality alters cell behaviour. Here, we identify intracellular crowding as a key biophysical parameter altered by cell culture dimensionality, which directs cell fate over a mechano-metabolic axis. Specifically, culture dimensionality controlled intracellular crowding by altering cell volume, which was confirmed across multiple cell types and cell culture platforms. Using chondrogenesis as a model system, we demonstrated that dimensionality-induced intracellular changes lead to improved chondrogenic stem cell differentiation in microtissue culture via a FOXO1 signalling axis. Our findings highlight intracellular crowding as an important parameter of cell culture systems, and present a novel strategy for engineering biomimetic cell culture systems, which has implications for a multitude of applications including disease modelling, in vitro drug screening models, developmental biology, and cell-based therapies.
- Open Access
- 26 October 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (2) , e2300095
Single‐Step Biofabrication of In Situ Spheroid‐Forming Compartmentalized Hydrogel for Clinical‐Sized Cartilage Tissue Formation
3D cellular spheroids offer more biomimetic microenvironments than conventional 2D cell culture technologies, which has proven value for many tissue engineering applications. Despite beneficiary effects of 3D cell culture, clinical translation of spheroid tissue engineering is challenged by limited scalability of current spheroid formation methods. Although recent adoption of droplet microfluidics can provide a continuous production process, use of oils and surfactants, generally low throughput, and requirement of additional biofabrication steps hinder clinical translation of spheroid culture. Here, the use of clean (e.g., oil‐free and surfactant‐free), ultra‐high throughput (e.g., 8.5 mL min−1, 10 000 spheroids s−1), single‐step, in‐air microfluidic biofabrication of spheroid forming compartmentalized hydrogels is reported. This novel technique can reliably produce 1D fibers, 2D planes, and 3D volumes compartmentalized hydrogel constructs, which each allows for distinct (an)isotropic orientation of hollow spheroid‐forming compartments. Spheroids produced within ink‐jet bioprinted compartmentalized hydrogels outperform 2D cell cultures in terms of chondrogenic behavior. Moreover, the cellular spheroids can be harvested from compartmentalized hydrogels and used to build shape‐stable centimeter‐sized biomaterial‐free living tissues in a bottom‐up manner. Consequently, it is anticipated that in‐air microfluidic production of spheroid‐forming compartmentalized hydrogels can advance production and use of cellular spheroids for various biomedical applications.
- 26 October 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (2) , e2300095
Open AccessSingle‐Step Biofabrication of In Situ Spheroid‐Forming Compartmentalized Hydrogel for Clinical‐Sized Cartilage Tissue Formation
3D cellular spheroids offer more biomimetic microenvironments than conventional 2D cell culture technologies, which has proven value for many tissue engineering applications. Despite beneficiary effects of 3D cell culture, clinical translation of spheroid tissue engineering is challenged by limited scalability of current spheroid formation methods. Although recent adoption of droplet microfluidics can provide a continuous production process, use of oils and surfactants, generally low throughput, and requirement of additional biofabrication steps hinder clinical translation of spheroid culture. Here, the use of clean (e.g., oil‐free and surfactant‐free), ultra‐high throughput (e.g., 8.5 mL min−1, 10 000 spheroids s−1), single‐step, in‐air microfluidic biofabrication of spheroid forming compartmentalized hydrogels is reported. This novel technique can reliably produce 1D fibers, 2D planes, and 3D volumes compartmentalized hydrogel constructs, which each allows for distinct (an)isotropic orientation of hollow spheroid‐forming compartments. Spheroids produced within ink‐jet bioprinted compartmentalized hydrogels outperform 2D cell cultures in terms of chondrogenic behavior. Moreover, the cellular spheroids can be harvested from compartmentalized hydrogels and used to build shape‐stable centimeter‐sized biomaterial‐free living tissues in a bottom‐up manner. Consequently, it is anticipated that in‐air microfluidic production of spheroid‐forming compartmentalized hydrogels can advance production and use of cellular spheroids for various biomedical applications.
- Open Access
- 21 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Mass production of lumenogenic human embryoid bodies and functional cardiospheres using in-air-generated microcapsules
Organoids are engineered 3D miniature tissues that are defined by their organ-like structures, which drive a fundamental understanding of human development. However, current organoid generation methods are associated with low production throughputs and poor control over size and function including due to organoid merging, which limits their clinical and industrial translation. Here, we present a microfluidic platform for the mass production of lumenogenic embryoid bodies and functional cardiospheres. Specifically, we apply triple-jet in-air microfluidics for the ultra-high-throughput generation of hollow, thin-shelled, hydrogel microcapsules that can act as spheroid-forming bioreactors in a cytocompatible, oil-free, surfactant-free, and size-controlled manner. Uniquely, we show that microcapsules generated by in-air microfluidics provide a lumenogenic microenvironment with near 100% efficient cavitation of spheroids. We demonstrate that upon chemical stimulation, human pluripotent stem cell-derived spheroids undergo cardiomyogenic differentiation, effectively resulting in the mass production of homogeneous and functional cardiospheres that are responsive to external electrical stimulation. These findings drive clinical and industrial adaption of stem cell technology in tissue engineering and drug testing.
- 21 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Open AccessMass production of lumenogenic human embryoid bodies and functional cardiospheres using in-air-generated microcapsules
Organoids are engineered 3D miniature tissues that are defined by their organ-like structures, which drive a fundamental understanding of human development. However, current organoid generation methods are associated with low production throughputs and poor control over size and function including due to organoid merging, which limits their clinical and industrial translation. Here, we present a microfluidic platform for the mass production of lumenogenic embryoid bodies and functional cardiospheres. Specifically, we apply triple-jet in-air microfluidics for the ultra-high-throughput generation of hollow, thin-shelled, hydrogel microcapsules that can act as spheroid-forming bioreactors in a cytocompatible, oil-free, surfactant-free, and size-controlled manner. Uniquely, we show that microcapsules generated by in-air microfluidics provide a lumenogenic microenvironment with near 100% efficient cavitation of spheroids. We demonstrate that upon chemical stimulation, human pluripotent stem cell-derived spheroids undergo cardiomyogenic differentiation, effectively resulting in the mass production of homogeneous and functional cardiospheres that are responsive to external electrical stimulation. These findings drive clinical and industrial adaption of stem cell technology in tissue engineering and drug testing.
- Open Access
- 13 August 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (25) , e2301552
Microfluidic Generation of Thin‐Shelled Polyethylene Glycol‐Tyramine Microgels for Non‐Invasive Delivery of Immunoprotected β‐Cells
Transplantation of microencapsulated pancreatic cells is emerging as a promising therapy to replenish β‐cell mass lost from auto‐immune nature of type I diabetes mellitus (T1DM). This strategy intends to use micrometer‐sized microgels to provide immunoprotection to transplanted cells to avoid chronic application of immunosuppression. Clinical application of encapsulation has remained elusive due to often limited production throughputs and body's immunological reactions to implanted materials. This article presents a high‐throughput fabrication of monodisperse, non‐immunogenic, non‐degradable, immunoprotective, semi‐permeable, enzymatically‐crosslinkable polyethylene glycol‐tyramine (PEG‐TA) microgels for β‐cell microencapsulation. Monodisperse β‐cell laden microgels of ≈120 µm, with a shell thickness of 20 µm are produced using an outside‐in crosslinking strategy. Microencapsulated β‐cells rapidly self‐assemble into islet‐sized spheroids. Immunoprotection of the microencapsulated is demonstrated by inability of FITC‐IgG antibodies to diffuse into cell‐laden microgels and NK‐cell inability to kill microencapsulated β‐cells. Multiplexed ELISA analysis on live blood immune reactivity confirms limited immunogenicity. Microencapsulated MIN6β1 spheroids remain glucose responsive for 28 days in vitro, and able to restore normoglycemia 5 days post‐implantation in diabetic mice without notable amounts of cell death. In short, PEG‐TA microgels effectively protect implanted cells from the host's immune system while being viable and functional, validating this strategy for the treatment of T1DM.
- 13 August 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (25) , e2301552
Open AccessMicrofluidic Generation of Thin‐Shelled Polyethylene Glycol‐Tyramine Microgels for Non‐Invasive Delivery of Immunoprotected β‐Cells
Transplantation of microencapsulated pancreatic cells is emerging as a promising therapy to replenish β‐cell mass lost from auto‐immune nature of type I diabetes mellitus (T1DM). This strategy intends to use micrometer‐sized microgels to provide immunoprotection to transplanted cells to avoid chronic application of immunosuppression. Clinical application of encapsulation has remained elusive due to often limited production throughputs and body's immunological reactions to implanted materials. This article presents a high‐throughput fabrication of monodisperse, non‐immunogenic, non‐degradable, immunoprotective, semi‐permeable, enzymatically‐crosslinkable polyethylene glycol‐tyramine (PEG‐TA) microgels for β‐cell microencapsulation. Monodisperse β‐cell laden microgels of ≈120 µm, with a shell thickness of 20 µm are produced using an outside‐in crosslinking strategy. Microencapsulated β‐cells rapidly self‐assemble into islet‐sized spheroids. Immunoprotection of the microencapsulated is demonstrated by inability of FITC‐IgG antibodies to diffuse into cell‐laden microgels and NK‐cell inability to kill microencapsulated β‐cells. Multiplexed ELISA analysis on live blood immune reactivity confirms limited immunogenicity. Microencapsulated MIN6β1 spheroids remain glucose responsive for 28 days in vitro, and able to restore normoglycemia 5 days post‐implantation in diabetic mice without notable amounts of cell death. In short, PEG‐TA microgels effectively protect implanted cells from the host's immune system while being viable and functional, validating this strategy for the treatment of T1DM.
- Open Access
Scalable Production of Size-Controlled Cholangiocyte and Cholangiocarcinoma Organoids within Liver Extracellular Matrix-Containing Microcapsules
Advances in biomaterials, particularly in combination with encapsulation strategies, have provided excellent opportunities to increase reproducibility and standardization for cell culture applications. Herein, hybrid microcapsules are produced in a flow-focusing microfluidic droplet generator combined with enzymatic outside-in crosslinking of dextran-tyramine, enriched with human liver extracellular matrix (ECM). The microcapsules provide a physiologically relevant microenvironment for the culture of intrahepatic cholangiocyte organoids (ICO) and patient-derived cholangiocarcinoma organoids (CCAO). Micro-encapsulation allowed for the scalable and size-standardized production of organoids with sustained proliferation for at least 21 days in vitro. Healthy ICO (n = 5) expressed cholangiocyte markers, including KRT7 and KRT19, similar to standard basement membrane extract cultures. The CCAO microcapsules (n = 3) showed retention of stem cell phenotype and expressed LGR5 and PROM1. Furthermore, ITGB1 was upregulated, indicative of increased cell adhesion to ECM in microcapsules. Encapsulated CCAO were amendable to drug screening assays, showing a dose-response response to the clinically relevant anti-cancer drugs gemcitabine and cisplatin. High-throughput drug testing identified both pan-effective drugs as well as patient-specific resistance patterns. The results described herein show the feasibility of this one-step encapsulation approach to create size-standardized organoids for scalable production. The liver extracellular matrix-containing microcapsules can provide a powerful platform to build mini healthy and tumor tissues for potential future transplantation or personalized medicine applications.
Open AccessScalable Production of Size-Controlled Cholangiocyte and Cholangiocarcinoma Organoids within Liver Extracellular Matrix-Containing Microcapsules
Advances in biomaterials, particularly in combination with encapsulation strategies, have provided excellent opportunities to increase reproducibility and standardization for cell culture applications. Herein, hybrid microcapsules are produced in a flow-focusing microfluidic droplet generator combined with enzymatic outside-in crosslinking of dextran-tyramine, enriched with human liver extracellular matrix (ECM). The microcapsules provide a physiologically relevant microenvironment for the culture of intrahepatic cholangiocyte organoids (ICO) and patient-derived cholangiocarcinoma organoids (CCAO). Micro-encapsulation allowed for the scalable and size-standardized production of organoids with sustained proliferation for at least 21 days in vitro. Healthy ICO (n = 5) expressed cholangiocyte markers, including KRT7 and KRT19, similar to standard basement membrane extract cultures. The CCAO microcapsules (n = 3) showed retention of stem cell phenotype and expressed LGR5 and PROM1. Furthermore, ITGB1 was upregulated, indicative of increased cell adhesion to ECM in microcapsules. Encapsulated CCAO were amendable to drug screening assays, showing a dose-response response to the clinically relevant anti-cancer drugs gemcitabine and cisplatin. High-throughput drug testing identified both pan-effective drugs as well as patient-specific resistance patterns. The results described herein show the feasibility of this one-step encapsulation approach to create size-standardized organoids for scalable production. The liver extracellular matrix-containing microcapsules can provide a powerful platform to build mini healthy and tumor tissues for potential future transplantation or personalized medicine applications.
- Open Access
- 1 March 2020
- Published by Elsevier in Materials Today Bio
- Vol. 6, 100047
Enzymatic outside-in cross-linking enables single-step microcapsule production for high-throughput three-dimensional cell microaggregate formation
- 1 March 2020
- Published by Elsevier in Materials Today Bio
- Vol. 6, 100047
Open AccessEnzymatic outside-in cross-linking enables single-step microcapsule production for high-throughput three-dimensional cell microaggregate formation
- Open Access
- 16 April 2019
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 19 (11) , 1977-1984
On-the-fly exchangeable microfluidic nozzles for facile production of various monodisperse micromaterials
Exchangeable microfluidic nozzles enable the facile production of a wide variety of micromaterials using a single cleanroom-free manufactured microfluidic device.
- 16 April 2019
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 19 (11) , 1977-1984
Open AccessOn-the-fly exchangeable microfluidic nozzles for facile production of various monodisperse micromaterials
Exchangeable microfluidic nozzles enable the facile production of a wide variety of micromaterials using a single cleanroom-free manufactured microfluidic device.